

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

## Modified Hammerhead Ribozymes as Potential Therapeutics

Joachim W. Engels<sup>a</sup>; Michaela Scherr<sup>a</sup>; Arnold Ganser<sup>b</sup>; Manuel Grez<sup>c</sup>; Valentin Wittmann<sup>a</sup>

<sup>a</sup> Institut für Organische Chemie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany <sup>b</sup> Medizinische Hochschule Hannover, Hannover, Germany <sup>c</sup> Georg-Speyer-Haus, Frankfurt am Main, Germany

**To cite this Article** Engels, Joachim W. , Scherr, Michaela , Ganser, Arnold , Grez, Manuel and Wittmann, Valentin(1998) 'Modified Hammerhead Ribozymes as Potential Therapeutics', *Nucleosides, Nucleotides and Nucleic Acids*, 17: 9, 1685 — 1696

**To link to this Article:** DOI: 10.1080/07328319808004702

**URL:** <http://dx.doi.org/10.1080/07328319808004702>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Modified Hammerhead Ribozymes as Potential Therapeutics

Joachim W. Engels\*, Michaela Scherr, Arnold Ganser<sup>1</sup>, Manuel Grez<sup>2</sup>  
and Valentin Wittmann

Institut für Organische Chemie, Johann Wolfgang Goethe-Universität  
Marie-Curie-Str. 11, D-60439 Frankfurt am Main, Germany

<sup>1</sup>Medizinische Hochschule Hannover, 30625 Hannover, Germany

<sup>2</sup>Georg-Speyer-Haus, 60596 Frankfurt am Main, Germany


**ABSTRACT:** Hammerhead ribozymes were modified in the 2'-position by fluoro-, amino-, deoxy-, O-methyl- and methoxyethoxy-groups to stabilize against degradations. They were tested for their ability to cut specifically oncogenic *N-ras* RNA *in vitro*. Exogenous delivery by lipofection as well as viral vector mediated transfection showed comparable results in reducing *N-ras* mRNA.

**INTRODUCTION:** Synthetic oligonucleotides show great promise as therapeutic entities, be it by acting as antisense, ribozyme or triplex constructs. The latter are based on RNA-structures derived from nature which have to be suitably modified in order to be applicable in cells or living organism.

One of the best understood ribozymes, the hammerhead ribozyme<sup>1</sup>, originates from plant viruses. For efficient cleavage a consensus sequence is required consisting of a NUH base triplett at the juncture of three base paired stems including 11 consensus nucleotides (FIG. 1). Whereas originally the reaction takes place in *cis* under single turnover conditions it has been demonstrated that it also behaves like a true enzyme cleaving in *trans*. In the presence of Mg<sup>2+</sup> transesterification leaves a 5'-hydroxyl on one side and a 2'-3'-cyclic phosphate on the other side<sup>2</sup>. Based on a good number of analog structure

---

\* correspondence to J.W. Engels, Phone: +49 69 7982 9150; Fax: +49 69 7982 9148  
e-mail: engels@ews1.org.chemie.uni-frankfurt.de



**FIG. 1.** Consensus sequence of the hammerhead ribozyme. Numbering system according to Hertel et al.<sup>3</sup> Conserved nucleotides are shaded. N = any nucleotide; P = A or G; Y = U or C; H = A, C or U.

studies the design of therapeutic ribozymes is possible now. Important prerequisites which have to be considered in the design are the target delivery, the stability in cells and the efficient catalysis in destroying the target mRNA.

For target delivery we choose lipofection as one method (exogenous application) and viral vector-mediated delivery (endogenous application) as the other alternative. Since unmodified RNA is unstable in sera chemical modification has to be performed for exogenous delivery. Initially we relied on the studies of Eckstein et al.<sup>4</sup> in choosing sugar modifications as 2'-fluoro and 2'-amino- substituents. Furthermore 2'-deoxy-, 2'-O-methyl and 2'-methoxyethoxy substituents were tested. For all these modifications efficient catalysis was determined. The introduction of phosphothioates at the ends led to a nearly complete stability.

The growth and differentiation of cells depends on a variety of parameters one of which is a complex signal transduction. The proteins coded by the three *ras*-genes (Ha-*ras*, N-*ras*, Ki-*ras*) are involved in the cell signal transduction and are members of the super gene family of small GTP/GDP binding proteins<sup>5</sup>. *Ras* mutations have been found in tumours<sup>6</sup>, neuroblastoma, acute myeloblastic leukaemia (AML), chronic myelogenous

leukaemia (CML) and multiple myeloma<sup>7</sup>. Studies of *ras*-oncogenes in tumours have revealed several point mutations in codon 12, 13, 59 or 61 which cause structural changes in the GTP binding site and reduce GTPase activity. Mutant *ras* proteins, having a reduced ability to hydrolyze GTP, remain in the active state and thus stimulate cell growth or differentiation autonomously. The inhibition of this incorrect signal transduction by ribozymes may lead to an efficient anti-cancer therapy.

**RESULT AND DISCUSSION:** In the present study we report the synthesis and catalytic properties of several hammerhead ribozymes targeted against mutant *N-ras* transcripts. As outlined above essential point mutations in codon 12 and 13 of the mRNA are responsible for autonomous growth. On the DNA-level (FIG. 2) these mutations create the consensus motif (NUH) for hammerhead recognition.

Thus, we constructed two ribozymes targeted against these regions named MRE763C and MRE764U. GC transversion at position 763 generates a GUC triplet which is targeted by the ribozyme MRE763C (FIG. 3A). Ribozyme MRE764U is targeted against a second GT transversion at position 764 generating a GUU triplet (FIG. 3B).


The ribozymes MRE763C and MRE764U are highly specific as they only cleave oncogenic *N-ras* sequences containing a point mutation in codon 13 at position 763 or 764. Incubation of MRE763C with a 849 nucleotide long mutant *N-ras* transcript resulted in the expected cleavage products of 534 and 315 bases (FIG 4A). The same result was obtained for ribozyme MRE764U (data not shown). In contrast, incubation of MRE763C with transcripts containing the wild-type *N-ras* sequences did not result in any detectable substrate (FIG 4B).

Since the final goal of our experiments was to demonstrate the efficiency of these ribozymes in cell culture, pyrimidine ribonucleotides containing 2'-hydroxyl substitutions were used for increasing the stability of the oligoribonucleotides against degradation by RNases. The modifications tested were 2'-deoxy, 2'-O-methyl-, 2'-O-methoxyethoxy-, 2'-fluoro-deoxypyrimidine and 2'-amino-deoxyuridine (FIG. 5).

The modified ribozymes were incubated in cell culture media at 37°C for up to 120 h and assayed for cleavage as described<sup>8</sup>. While the unmodified ribozyme was degraded within half a minute, the introduction of three phosphorothioate linkages at the 3'-end of


1	2	3	4	5	6	7	8	9	10	11	12	13		188	189	
Met	Thr	Glu	Tyr	Lys	Leu	Val	Val	Val	Gly	Ala	Gly	Gly	.....	Leu	Ser	wildtype c-N-ras gene
ATG	ACG	GAA	TAT	AAG	CTG	GTG	GTG	GTT	GGA	GCA	G	GGT	.....	CTC	TCC	
												↓ CGT	cleavage site			
Met	Thr	Glu	Tyr	Lys	Leu	Val	Val	Val	Gly	Ala	Gly	Arg	.....	Leu	Ser	activated c-N-ras gene

**FIG. 2.** Point mutation in codon 13 GGT (Gly) → CGT (Arg) leads to an activated N-ras oncogene and to a potential ribozyme cleavage site GUG → GUC.




**FIG 3.** Schematic representation of the chemically synthesized hammerhead ribozymes directed against oncogenic N-ras mRNA. The cleavage site is indicated by an arrow and the point mutation is shaded.

the ribozyme and one at the 5'-end increased the half-life of ribozymes to 2-3 minutes. Other modifications (e.g. 2'-fluoro-2'-deoxyuridine) led to a further increase in stability (TAB. 1). Finally, complete substitution of all pyrimidine nucleotides (e.g. 2'-fluoro-2'-deoxycytidine or 2'-methoxy-ethoxy) prevented ribozyme degradation for up to 80 h. Most of the modified ribozymes were still capable of cleaving the oncogenic N-ras transcripts. Introduction of 2'-fluoro-2'-deoxypyrimidine into ribozymes led to a 2- or 3-fold decrease in catalytic activity compared to the unmodified ones which did not depend on the presence or absence of terminal phosphorothioates (TAB. 2). In contrast, substitution of the 2'-hydroxyl group by 2'-O-methyl-2'-deoxyuridine/cytidine or 2'-



**FIG 4.** Kinetics of ribozyme cleavage with full-length *N-ras* transcripts. MRE763C was incubated with a 849-nucleotide-long oncogenic (A) or wildtype (B) *N-ras* transcript for 1h at 37°C. The substrate concentrations used were 2 nM and ribozyme concentrations were 20, 40, 50, 60, 80, 100, or 120 nM (lane 2-8) in the presence of 10 mM MgCl<sub>2</sub>. Lane 1 shows the untreated substrate.

methoxyethoxy-2'-deoxyuridine/cytidine led to a complete loss of activity. The best results were obtained by introducing 2'-amino-2'-deoxy uridine in the U<sub>4</sub>, U<sub>7</sub>-positions in the 2'-fluoro or 2'-methoxyethoxy modified ribozyme<sup>4,8,9</sup>. Recently by heteronuclear NMR we could show that 2'-fluoro groups in RNA not only change the thermodynamic ratio of the 2'-3'-endo sugar conformation but also influence their kinetic exchange rate by slowing down the pseudorotation phase<sup>10</sup>. According to these results, modified



**FIG. 5.** Different 2'-modifications of ribonucleosides incorporated into a ribozyme leading to stability against nucleases.

ribozymes containing 2'-fluoro-2'-deoxycytidine and 2'-fluoro-2'-deoxyuridine with or without phosphorothioate groups were used for the studies in cell culture.

To examine the cleavage properties of the modified ribozymes *ex vivo*, a *N-ras*/luciferase fusion minigene was constructed. A 452 bp *N-ras* DNA fragment, containing 50 bp 5'-untranslated sequences, the *N-ras* translation initiation codon and sequences coding for the first 134 amino acids of wildtype or mutant *N-ras*, was fused in frame with the firefly luciferase gene changing the AUG translation initiation codon of the luciferase gene to AUA. In this construct the expression of the luciferase gene is under the control of the *N-ras* gene, thus, cleavage of *N-ras* sequences by ribozymes can be monitored by the reduction in luciferase activity.

**TABLE 1.** Stability of modified ribozymes in cell culture media.

Ribozyme	Cell supernatants (half-life-times)
Unmodified	0.5 min
<b>S</b>	3.0 min
<b>S, FU</b>	10.0 min
<b>FU, FC</b>	50 h
<b>FU, FC, U<sub>4</sub>U<sub>7</sub>-NH<sub>2</sub></b>	50 h
<b>S, FU, OMeC</b>	80 h
<b>S, OMeU, OMeC</b>	80 h
<b>S, dU, dC</b>	80 h
<b>S, FU, FC</b>	80 h
<b>EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-OH</b>	30.0 min
<b>EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-NH<sub>2</sub></b>	80 h
<b>EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-F</b>	80 h
<b>EtOMeU, EtOMeC</b>	80 h
<b>S, EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-NH<sub>2</sub></b>	80 h
<b>S, EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-F</b>	80 h

**TABLE 2.** Catalytic efficiencies of several modified hammerhead ribozymes with *in vitro* transcribed N-ras RNA (nd, not detectable).

Ribozyme	Modification	$k_{\text{react}}$ [10 <sup>-6</sup> s <sup>-1</sup> ]	$K_M$ [nM ]	$k_{\text{react}}/K_M$ [s <sup>-1</sup> M <sup>-1</sup> ]	$k_{\text{react}}/K_M$ (relative)
MRE764U		137	113	1212	1
	<b>FU, FC</b>	62	120	516	0.40
MRE763C		266	71	3752	1
	<b>FU, FC</b>	50	39	1266	0.340
	<b>FU, FC, U<sub>4</sub>U<sub>7</sub>-NH<sub>2</sub></b>	173	71	2437	0.650
	<b>EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-OH</b>	147	51	2882	0.770
	<b>EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-NH<sub>2</sub></b>	173	73	2370	0.630
	<b>EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-F</b>	39	135	288	0.077
	<b>EtOMeU, EtOMeC</b>	nd	nd	nd	nd
	<b>OMeU, OMeC</b>	nd	nd	nd	nd
	<b>S, FU, FC</b>	51	44	1159	0.300
	<b>S, EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-F</b>	nd	nd	nd	nd
	<b>S, EtOMeU, EtOMeC, U<sub>4</sub>U<sub>7</sub>-NH<sub>2</sub></b>	27	190	142	0.038




HeLa cells were transfected with plasmids containing either wild-type or mutant *N-ras*/luciferase fusion gene under the transcriptional control of a CMV promoter/enhancer element and neomycin selection. The HeLa cell clones C#3 (GGT to CGT mutation at position 763), T#4 (GGT to GTT transversion at position 764) and W#2 (wildtype *N-ras* sequence) showed the highest luciferase activity and were chosen for all subsequent experiments. These clones were transiently transfected with the ribozymes MRE763C and MRE764U using LipofectAMINE™. As a control for unspecific cleavage, a ribozyme containing an active catalytic site but no homology to the target *N-ras* sequence was used (nonsense ribozyme). It was chosen for 100% luciferase activity (reference). Similarly, catalytically inactive ribozymes containing an adenosine residue instead of guanosine at position 5 (iMRE763C and iMRE764U) were used to estimate the reduction in luciferase activity caused solely by the hybridization of the ribozymes to the target sequences (antisense effect).

The ribozyme MRE763C, targeted against the mutation at position 763 of the *N-ras*/luciferase mRNA, was most effective in inhibiting luciferase gene expression. An inhibition of up to 60% was observed at a ribozyme concentration of 10 μM (FIG. 6). These results were confirmed by the studies with ribozyme MRE764U. A minor decrease in luciferase activity (20%) was seen with the inactive ribozymes iMRE764U and iMRE763C, which can be explained by an antisense effect.

When HeLa cell clone W#2, which expresses wild-type *N-ras* sequence, was treated with MRE763C a 20% reduction in luciferase was observed. This value is within the range of the luciferase activity obtained from HeLa cells treated with the inactive form of the ribozyme (iMRE763C) and thus is probably due to an antisense effect of ribozyme MRE763C on the wild-type *N-ras*/luciferase mRNA.

Although the reduction in luciferase activity suggests that the ribozymes MRE764U and MRE763C cleave the fusion mRNA efficiently, a quantitative assessment of RNA molecules cleaved by the ribozymes is not possible by this assay. For that, a semi-quantitative RT-PCR reaction was established. Total RNA was isolated from clone C#3 by the guanidine-isothiocyanate method. Great care was taken<sup>11</sup> to estimate the degree of *N-ras*/luciferase mRNA cleavage during the extraction protocol by using an internal




**FIGURE 6.** Inhibition of luciferase activity in HeLa cells expressing oncogenic or wildtype *N-ras*/luciferase transcript by ribozymes.

control. For this, a 50 bp oligonucleotide was cloned within the *ras* sequences in the expression vector pcDNA3-LUCFUC and utilized as control in the RT-PCR.

Total RNA obtained from the HeLa cell clone C#3 was mixed with the internal standard RNA at a molar ratio of approximately 1. Upon reverse transcription, followed by a DNA-PCR the internal standard control should generate a 450 bp long PCR product, while amplification of a segment of the *N-ras*/luciferase fusion mRNA should generate a 394 bp DNA fragment.

The RT-PCR done on RNA obtained from clone C#3 treated with the nonsense ribozyme gave the expected product of 394 bp (FIG. 7, lane 5). Based on band intensities (FIG. 7, lane 4), no significant reduction was observed suggesting that treatment of the cells with a nonsense ribozyme does not reduce the amount of *N-ras*/luciferase transcripts. In addition, cleavage of the internal control was not observed. In contrast, treatment of cells with the active ribozyme MRE763C caused a significant reduction in *N-ras* transcripts. For clinical application of ribozymes, high catalytic efficiency, stability and good availability has to be achieved. Rapid degradation of oligoribonucleotides in living cells



**FIGURE 7.** RT-PCR analysis of total RNA. Lane 1, size marker (pBluescript II KS digested with *Hae*III); lane 2, RT-PCR product of obtained from 0.5 attomol internal standard RNA (450 bp); lane 3 control reaction with cellular RNA in which reverse transcriptase was omitted; lane 4, RT-PCR product obtained from cellular RNA before ribozyme treatment (394 bp); lane 5, RT-PCR products obtained from RNA after treatment with the nonsense ribozyme; lane 6, RT-PCR products obtained from RNA after treatment with the active ribozyme MRE763C.

diminishes availability of the ribozyme with a concomitant decrease in efficiency. Modifications usually lead to higher stability against digestion by nucleases but are often accompanied by a decrease in catalytic efficiency.

The *N-ras*/luciferase reporter system used in our studies provides a very sensitive assay to detect ribozyme activity, since the expression of the luciferase reporter gene depends on an intact *N-ras* sequence. This cell experiments revealed a reduction in luciferase activity of up to 55% in HeLa cells treated with MRE763C. A low but detectable antisense effect was also observed since incubation of HeLa cells expressing mutant *N-ras*/luciferase fusion transcripts with the inactive forms of MRE763C or MRE764U resulted in a 20% reduction in luciferase activity. The cleavage activity of ribozyme

MRE763C was restricted to mutated *N-ras* sequences, as the luciferase activity in HeLa cells expressing a wild-type *N-ras*/Luciferase transcript was not reduced above the levels expected from an antisense effect.

Since the half-life of a *ras*/luciferase protein was not known, we estimated the cleavage efficiency at the RNA level by analysing directly the amount of mRNA molecules cleaved by the ribozyme MRE763C. For this type of analysis an internal RNA standard is required, since cleavage of the substrate may also occur during the RNA extraction protocol<sup>11</sup>. The amount of RT-PCR product obtained from the standard RNA can be estimated by densitometric evaluation of the ethidium bromide bands in the agarose gel and thus can be correlated to the amounts of input RNA in the reaction. A systematic analysis of the amounts of *N-ras*/luciferase mRNA present in the HeLa clone C#3 was conducted by mixing different amounts of total cellular RNA with a constant amount of standard RNA. At a standard concentration of 0.5 attomol ( $3 \cdot 10^5$  RNA molecules) equivalent RT-PCR signals from total cellular RNA and standard RNA were observed, suggesting that the amount of *N-ras*/luciferase mRNA expressed in this cell clone was roughly  $3 \cdot 10^5$  molecules. After treatment of the cells with ribozyme MRE763C, no visible RT-PCR product was observed (FIG. 7, lane 6). *In vitro* studies showed that these ribozymes were specific for the oncogenic form of *N-ras*, since cleavage was observed only in a 849 nucleotides long transcript containing mutant but not wildtype *N-ras* sequences.

Altogether the chemical approach compares well to the gene therapy strategy in reducing the target mRNA.

**ACKNOWLEDGEMENT** We thank the Stiftung Stipendien-Fonds des Verbandes der Chemischen Industrie e.V. for financial support and F. Eckstein for helpful discussions. C. Klebba is gratefully acknowledged for oligonucleotide synthesis. We also thank R. Häner for the generous gift of 2'-methoxyethoxy-modified ribonucleosides.

## REFERENCES

1. Symons, R. H. *Annu. Rev. Biochem.* **1992** 61, 641-671.  
Bratty, J.; Chartrand, P.; Ferbeyre, G.; Cedergren, R. *Biochim. Biophys. Acta.* **1993** 1216, 345-359.

2. Hutchins, C. J.; Rathjen, P. D.; Forster, A. C.; Symons R. H. *Nucl. Acids Res.* **1986** *14*, 3627-3640.
3. Hertel, K.J.; Pardi, A.; Uhlenbeck, O.C.; Koizumi, M.; Ohtsuka, E.; Uesugi, S.; Cedergren, R.; Eckstein, F.; Gerlach, W.L.; Hodgson, R.; Symons, R.H. *Nucleic Acids Res.* **1992** *20*, 3252.
4. Heidenreich, O.; Eckstein, F. *J. Biol. Chem.* **1992** *267*, 1904-1909.  
Heidenreich, O.; Benseler, F.; Fahrenholz, A.; Eckstein, F. *J. Biol. Chem.* **1994** *269*, 2131-2138.
5. Edgington, S. M. *Bio/Technology* **1992** *10*, 152-154.
6. Bos, J. L. *Mutat. Res.* **1988** *195*, 255-271.
7. Portier, M.; Molès, J-P.; Mazars, G-R.; Jeanteur, P.; Bataille, R.; Klein, B.; Theillet, C. *Oncogene* **1992** *7*, 2539-2543.
8. Scherr, M.; Grez, M.; Ganser, A.; Engels, J. W. *J. of Biol. Chem.* **1997** *272*, 14304-14313.
9. Scherr, M.; Klebba, C.; Häner, R.; Ganser, A.; Engels, J. W. *Bioorg. & Medicinal Chem. Lett.* **1997** *7*, 1791-1796.
10. Reif, B.; Wittmann, V.; Schwalbe, H.; Griesinger, C.; Wörner, K.; Jahn-Hofmann, K.; Engels, J.W.; Bermel, W. *Helvetica Chimica Acta* **1997** *80*, in press.
11. Heidenreich, O.; Xiao, X.; Nerenberg, M. *Antisense & Nucleic Acid Drug Dev.* **1996** *6*, 141-144.  
Beck, J.; Nassal, M. *Nucleic Acids Res.* **1995** *23*, 4954-4962.